OCCASIONALLY SEEING IN PANS AND PANDAS
Treatments for acetylcholine autoimmunity (Myasthenia Gravis and related AChR-directed conditions)

Overview

• Acetylcholine autoimmunity most commonly presents as myasthenia gravis (MG), where antibodies attack acetylcholine receptors (AChR) or related proteins (e.g., MuSK, LRP4) at the neuromuscular junction.
• Treatments aim to relieve symptoms, reduce the autoimmune attack, and address any thymic pathology.
• The best approach is personalized: antibody type, disease severity, thymic status, age, pregnancy plans, and comorbidities guide choices.

⚠️ Important: This is general information. Always consult a clinician for diagnosis and an individualized plan. Vaccination status and infection risk (e.g., meningococcal vaccine with complement inhibitors) should be reviewed.

Core treatment strategies (by goal)

1) Symptom relief (rapid improvement of weakness)

• Acetylcholinesterase inhibitors
  • Example: Pyridostigmine
  • How it works: Increases acetylcholine at the neuromuscular junction to improve transmission.
  • Use: First-line for many with mild to moderate MG to improve daily function.
  • Notes: May cause GI upset, cramps, increased salivation; effects are temporary and dose-dependent.
• Short-term diagnostic aid (historical)
  • Edrophonium: used mainly for diagnosis in some settings; not a long-term treatment.

2) Acute management or crisis control

• Plasma exchange (plasmapheresis, PLEX)
  • When used: Myasthenic crisis or before surgery; rapid reduction of circulating antibodies.
• Intravenous immunoglobulin (IVIG)
  • When used: Alternative to PLEX or when PLEX isn’t available; temporary boost in symptoms.
• Both are bridging therapies; they don’t provide long-term disease modification.

3) Long-term disease modification and immune suppression

• Glucocorticoids
  • Example: Prednisone/prednisolone
  • Use: Effective for many MG patients; often started and tapered with careful monitoring for side effects.
  • Note: Long-term use requires management of osteoporosis, diabetes risk, weight gain, sleep disturbances, etc.
• Steroid-sparing immunosuppressants (to reduce steroid exposure)
  • Azathioprine
  • Mycophenolate mofetil
  • Methotrexate
  • Cyclosporine or tacrolimus
  • How they help: Reduce autoimmune activity and allow tapering of steroids.
• Thymectomy (surgical removal of the thymus)
  • Indications: Generalized AChR MG, especially with thymic hyperplasia or thymoma; may improve outcomes even without thymoma.
  • Note: Benefits can take months to years and depend on individual factors.

4) Targeted biologic and antibody-directed therapies (for refractory disease or specific antibodies)

• Rituximab (anti-CD20)
  • Best evidence: Particularly helpful for MuSK MG and for some AChR MG patients who are resistant to conventional therapy.
  • Practical note: Often used when other immunosuppressants fail or as a steroid-sparing strategy.
• Eculizumab (Soliris) – complement inhibitor
  • Indication: Generalized MG in adults (and some adolescents) who are positive for AChR antibodies.
  • Mechanism: Inhibits the complement cascade to prevent antibody-mediated damage at the neuromuscular junction.
  • Considerations: Requires meningococcal vaccination and monitoring for infection risk; high cost.
• FcRn inhibitors (to reduce pathogenic autoantibodies)
  • Efgartigimod alfa (Vyvgart)
    • How it works: FcRn blockade lowers circulating IgG antibodies, including pathogenic MG antibodies.
    • Evidence: Shown clinically meaningful improvement in generalized MG; can be used with other therapies.
  • Rozanolixizumab (investigational in MG; FcRn-targeted)
    • Status: Investigational in many regions; expect ongoing trials and evolving availability.
  • Practical note: Often used as a disease-modifying option in AChR MG; accessibility depends on regulatory approval and local guidelines.
• Other complement/biologic approaches (investigational)
  • Zilucoplan (a peptide C5 inhibitor, subcutaneous)
  • Additional agents in development or early trials
  • Status: Experimental in many places; discuss with a MG specialist if interested in trials.

How treatment choices align with MG subtypes

• AChR antibody-positive MG
  • Likely to respond to: Pyridostigmine, steroids with steroid-sparing agents, thymectomy (if applicable), eculizumab, rituximab (depending on course), and FcRn inhibitors (e.g., efgartigimod).
• MuSK antibody-positive MG
  • Often less responsive to acetylcholinesterase inhibitors alone.
  • Rituximab is particularly effective for MuSK MG.
  • Thymectomy is less consistently beneficial than in AChR MG.
  • FcRn inhibitors may also be beneficial; evidence is evolving.
• LRP4 or other less common antibodies
  • Management guided by disease severity; many principles overlap (symptomatic therapy, steroids, steroid-sparing agents, and biologics as indicated).

Practical treatment pathways (common scenarios)

• Mild, newly diagnosed MG
  • Start pyridostigmine for quick symptom relief.
  • Add low-dose prednisone with plan to taper.
  • Consider thymectomy if AChR-positive and thymic pathology is present.
  • Monitor for steroid-sparing opportunities (azathioprine or mycophenolate if needed).
• Generalized MG not fully controlled on steroids
  • Add or switch to a steroid-sparing agent (azathioprine or mycophenolate).
  • If refractory or MuSK-positive: consider rituximab.
  • Evaluate for FcRn inhibitor therapy (efgartigimod) or complement inhibition (eculizumab) if eligible.
• MG with a myasthenic crisis or prior to major surgery
  • Use PLEX or IVIG for rapid stabilization.
  • Plan long-term immunomodulation to reduce relapse risk.
• Refractory MG or patients with AChR MG
  • Consider eculizumab (with vaccination and infection risk management).
  • Consider FcRn inhibitors (like efgartigimod) and rituximab depending on antibody status and prior response.
  • Continue physical therapy, respiratory support as needed.

Safety, monitoring, and practical notes

• Vaccinations: Before starting complement inhibitors (e.g., eculizumab), ensure appropriate vaccines (meningococcal, pneumococcal, influenza) are up to date.
• Infection risk: Immunosuppressants raise risk of infections; discuss prophylaxis and monitoring with your clinician.
• Pregnancy: MG management changes during pregnancy; some therapies may be preferred or avoided. Coordinate with a neuromuscular specialist and obstetrician.
• Drug interactions and side effects: Each agent has specific risks (e.g., steroids: glucose intolerance, osteoporosis; azathioprine: marrow suppression; mycophenolate: GI intolerance; rituximab: infusion reactions, infection risk).
• Multidisciplinary care: Neurology, immunology/rheumatology, pulmonology (for respiratory muscle weakness), and sometimes thoracic surgery (thymectomy) are commonly involved.

Summary (take-home)

• The “best” treatments combine symptom relief with disease-modifying strategies tailored to antibody status and disease severity.
• Core pillars: acetylcholinesterase inhibitors for quick relief,
• Plasmapheresis for crisis-autoimmune antibody levels may rise over time. So intermittant use.
• IVIG for crises–dose, frequency? Brand?
• Steroids;
• Steroid-sparing immunosuppressants for long-term control; EXAMPLES?
• thymectomy when appropriate; When is it useful? UNSURE. 
• biologics (eculizumab, FcRn inhibitors, rituximab–DOSE MUST START WITH A DROP) for refractory or specific antibody subtypes.
• Ongoing advances (notably FcRn inhibitors and complement inhibitors) are expanding options for many patients with acetylcholine autoimmunity.

---

ARE THERE SUBTYPES OF THIS AUTOIMMUNITY? UNSURE.